Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 279Head & Neck 176Thoracic 37Tumor-Agnostic 11CNS 10Breast 9Gynecologic 6Genitourinary 6Other solid neoplasm 5Sarcoma 4Lymphoid 3Dermatologic 3Other neoplasm 2Plasma cell 1Other hematologic neoplasm 1Myeloid 1

Conditions

Multiple Myeloma 1

Interventions

Dexamethasone 479Lenalidomide 297Cyclophosphamide 271Bortezomib 266Melphalan 211Calcium Dobesilate 188fludarabine phosphate 121daratumumab 121Peripheral Blood Stem Cell Transplantation 101fludarabine 99carfilzomib 98Thalidomide 94pomalidomide 92Filgrastim 92Whole-Body Irradiation 88Mycophenolic Acid 88Busulfan 80Tacrolimus 75Granulocyte Colony-Stimulating Factor 72dexamethasone acetate 65ixazomib 62Cyclosporine 59dexamethasone 21-phosphate 56Antilymphocyte Serum 51auricularum 50isatuximab 42Radiotherapy 41Etoposide 40Stem Cell Transplantation 39Methotrexate 33

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Cetuximab × Plasma cell × Clear all
NCT00368121 2012-07-13

EMMA-1

University of Cologne

Phase 2 Terminated
13 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡